No connection

Search Results

HYFT vs MGX

HYFT
MindWalk Holdings Corp.
BEARISH
Price
$1.07
Market Cap
$50.0M
Sector
Healthcare
AI Confidence
85%
MGX
Metagenomi Therapeutics, Inc.
BEARISH
Price
$1.40
Market Cap
$52.7M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
HYFT
--
MGX
--
Forward P/E
HYFT
--
MGX
-0.84
P/B Ratio
HYFT
4.68
MGX
0.33
P/S Ratio
HYFT
1.78
MGX
2.09
EV/EBITDA
HYFT
-4.06
MGX
0.74

Profitability

Gross Margin
HYFT
57.19%
MGX
-274.58%
Operating Margin
HYFT
-88.36%
MGX
-623.04%
Profit Margin
HYFT
-43.6%
MGX
0.0%
ROE
HYFT
-58.82%
MGX
-44.66%
ROA
HYFT
-18.94%
MGX
-21.99%

Growth

Revenue Growth
HYFT
52.4%
MGX
-59.3%
Earnings Growth
HYFT
--
MGX
--

Financial Health

Debt/Equity
HYFT
0.24
MGX
0.26
Current Ratio
HYFT
3.74
MGX
7.22
Quick Ratio
HYFT
3.4
MGX
7.08

Dividends

Dividend Yield
HYFT
--
MGX
--
Payout Ratio
HYFT
0.0%
MGX
0.0%

AI Verdict

HYFT BEARISH

MindWalk Holdings Corp. (HYFT) exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness in fundamental health. While the company shows strong top-line revenue growth of 52.4% and maintains a healthy current ratio of 3.74, it is unable to translate this growth into profitability, with an operating margin of -88.36%. The stock is currently in a sharp technical downtrend, losing over 40% of its value in the last six months. Despite a high analyst target price of $4.00, the consistent failure to meet earnings estimates (0/4 beats) suggests a significant disconnect between analyst expectations and operational reality.

Strengths
Strong YoY revenue growth of 52.40%
Healthy liquidity with a current ratio of 3.74
Low leverage with a Debt/Equity ratio of 0.24
Risks
Critical financial health (Piotroski F-Score 1/9)
Severe lack of profitability with ROE at -58.82%
Consistent earnings misses (Average surprise -106.63% over last 4 quarters)
MGX BEARISH

MGX exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company suffers from a catastrophic negative gross margin (-274.58%) and a significant decline in year-over-year revenue (-59.30%), suggesting a failing or highly inefficient business model. While the current ratio of 7.22 provides a temporary liquidity cushion, the combination of bearish insider selling by the CEO and CFO and a 0/100 technical trend suggests a lack of confidence in near-term recovery. Despite a high analyst target price of $9.33, the deterministic data points to a high-risk speculative asset in a downward spiral.

Strengths
Strong short-term liquidity (Current Ratio: 7.22)
Low leverage (Debt/Equity: 0.26)
Trading significantly below book value (P/B: 0.33)
Risks
Critical fundamental weakness (Piotroski F-Score: 0/9)
Negative gross margins indicating unsustainable cost structure
Severe revenue contraction (-59.30% YoY)

Compare Another Pair

HYFT vs MGX: Head-to-Head Comparison

This page compares MindWalk Holdings Corp. (HYFT) and Metagenomi Therapeutics, Inc. (MGX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile